晚期ROS1重排肺癌患者血栓栓塞事件高风险
该回顾性多中心研究纳入西班牙23个中心和葡萄牙1个中心的58例晚期ROS1重排肺癌患者,旨在分析血栓栓塞事件(TEs)的发生率、预测风险因素及其对总生存的影响。结果显示TEs发生率为46.6%(27例),中位随访19个月,中位总生存52个月,发生TEs患者中位总生存50个月(HR=1.12,95%CI 0.47-2.65,P=0.78)。多数事件为静脉血栓(24例,89%),且67%(18例)发生在门诊,48%(13例)发生在围诊断期。
要点
- 晚期ROS1重排肺癌患者TEs发生率高达46.6%。
- 近半数TEs发生在癌症诊断前后(围诊断期)。
- TEs与总生存无显著关联(HR=1.12,P=0.78)。
核心结论
- 晚期ROS1重排肺癌患者血栓栓塞事件发生率高,尤其在诊断过程中需临床医生特别关注。
研究设计与样本
- 回顾性分析西班牙23个中心和葡萄牙1个中心的58例晚期ROS1重排肺癌患者。
主要发现
- 中位随访19个月(范围1-78个月),TEs发生率为46.6%(27例)。
- 总人群中位总生存52个月,发生TEs患者中位总生存50个月,HR=1.12(95%CI 0.47-2.65),P=0.78。
- 多数TEs为静脉事件(24例,89%),67%(18例)发生在门诊,48%(13例)发生在围诊断期。
临床怎么用
- 对晚期ROS1重排肺癌患者应警惕血栓栓塞事件,特别是在诊断期间。
- 可考虑设计前瞻性研究评估抗血栓预防措施以降低TEs风险。
局限性
- 本研究为小样本描述性研究,存在局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Based on the high incidence of thromboembolic events (TEs) observed in lung adenocarcinomas with ALK translocations and taking into account the biological proximity of ROS1 and ALK, we conducted a retrospective analysis of patients with advanced lung carcinoma carrying rearrangements in ROS1 from 23 centres in Spain and one centre in Portugal. METHODS: The main objective of the study was to analyse the incidence of TE in this population, looking for predictive risk factors, and its impact on overall survival. RESULTS: A total of 58 patients were included. The incidence of TEs throughout the disease was 46.6% (n = 27) with a median follow-up of 19 months (range: 1-78 months) and a median overall survival of 52 months in the total population and 50 months for the patients presenting TEs, with a hazards ratio of 1.12 (95% confidence interval: 0.47-2.65) p = 0.78. The majority of the events were venous (n = 24; 89%) and occurred in the ambulatory setting (n = 18; 67%). Almost half of the patients (n = 13; 48%) presented the TE in the peri-diagnostic period. CONCLUSIONS: The high incidence of thrombosis, especially during the cancer diagnosis process, requires special attention from a clinician. Despite the limitations of such a small descriptive study, its results are in accordance with previously reported data. It would be important to design prospective studies of antithrombotic prophylaxis in this population because of their possible impact in reducing the risk of TEs.
引用
- Muñoz-Unceta N, Zugazagoitia J, Manzano A, et al. High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1. Eur J Cancer. 2020. PMID: 33166862. doi:10.1016/j.ejca.2020.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。